World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: Netherlands Trial Register
Last refreshed on: 28 April 2013
Main ID:  NTR917
Date of registration: 20/02/2007
Primary sponsor: Leiden University Medical Center (LUMC), Department of Neurology
Public title: STOP PAIN
Scientific title: Septal closure of PFO- does it prevent migraine? - STOP PAIN
Date of first enrolment: 1/4/2007
Target sample size: 50
Recruitment status: other
URL:  http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=917
Study type:  intervention
Study design:  Randomised: Yes; Masking: Double; Control: Placebo; Group: Parallel; Type: [default]  
Countries of recruitment
The Netherlands
Contacts
Name: H.  Koppen
Address:  Leiden University Medical Center (LUMC), Department of Neurology Postbus 9600 2300 RC Leiden The Netherlands
Telephone: h.koppen@lumc.nl
Email:
Affiliation: 
Name: H.  Koppen
Address:  Leiden University Medical Center (LUMC), Department of Neurology Postbus 9600 2300 RC Leiden The Netherlands
Telephone: h.koppen@lumc.nl
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: 1. Migraine with aura;
2. Migraine history of at least 1 year
at least 2 migraine attacks/month
at least 1 migraine attack with aura;
3. Failure or intolerance to 2 classes prophylactic migraine medication;
4. Aged 18-50;
5. Right to left shunt suitable for closure.

Exclusion criteria: 1. History of 15 or more headache days per month;
2. Taking preventive medication for other conditions other than migraine;
3. 8 or more non-migraine headache days/month;
4. Overuse of acute headache medication( use on 10 or more days/month;
5. Severe central nervous system disease
previous surgical or device closure of PFO/ASD;
6. Atrial heart valve;
7. Pacemaker or ICD implanted within past 3 months;
8. History of atrial fibrillation;
9. Undergoing dialysis;
10. NYHA class 3 or 4 cardiac failure;
11. Pregnant;
12. Anticoagulation


Age minimum:
Age maximum:
Gender:
Health Condition(s) or Problem(s) studied
Migraine, Foramen ovale persistens, Closure

Intervention(s)
In migraine patients with aura who have a patent foramen ovale, transcatheter device closure PFO after randomization will be performed or sham procedure
Primary Outcome(s)
Number of patients experiencing 50% reduction of migraine in closure group compared with sham group.
Secondary Outcome(s)
Mean values of monthly migraine periods
QoL using headache impact test questionaire.
Secondary ID(s)
ISRCTN54702843
Source(s) of Monetary Support
Leiden University Medical Center (LUMC), Department of Neurology, St Jude Medical inc - Belgium
Secondary Sponsor(s)
St Jude Medical inc
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history